ChemX Materials has drawn a further $167,000 under its unsecured Ovay loan while pursuing a recapitalisation that could support a return to ASX trading. The company reported no cash on hand at quarter-end and remains suspended after almost two years.
- $167,000 drawn under Ovay facility during the September quarter
- $434,000 remains available from the $1.2 million loan facility
- Company reported no cash and an estimated 2.6 quarters of funding
- Shares remain suspended from ASX trading since 19 December 2024
- Annual general meetings scheduled for 5 November 2026
ChemX Funding Runway Narrows During Suspension
ChemX Materials Limited (ASX:CMX) has 2.6 quarters of estimated funding available, but no cash on hand, as it continues working towards a recapitalisation and possible return to trading. The company drew $167,000 during the September quarter under its unsecured loan facility with Ovay Pty Ltd, leaving $434,000 available from the $1.2 million cap.
The latest figures extend a holding pattern that has now lasted almost two years. ChemX shares have remained suspended from ASX trading since 19 December 2024, and the board said it continues to progress plans for a potential return to trading, without giving a timetable or confirming that a relisting will occur.
Loan Funding Supports Restructuring Work
The Ovay arrangement, formalised in March, carries interest of 15% a year and has a maturity date of 13 March 2027. The facility is intended to cover funds previously advanced and future advances while ChemX progresses its recapitalisation and restructuring activities. Its accumulated facility limit, including interest, is to convert into fully paid ordinary shares at the issue price of a future capital raising connected with a relisting.
The financing is the same mechanism outlined in the $1.2 million Ovay facility, which was reported as convertible into shares upon relisting. That conversion structure means the eventual share impact cannot be assessed from this quarterly report alone because no future capital raising, issue price or relisting transaction has been confirmed.
No Exploration Activity During the Quarter
Operationally, ChemX reported no exploration activity and remained focused on maintaining working capital while developing and testing recapitalisation and restructuring models for property acquisition and development opportunities. The Appendix 5B recorded $167,000 in administration and corporate outflows, matched by $167,000 in borrowings, with cash and cash equivalents at quarter-end reported as nil.
The company also disclosed $40,000 in payments to a director-related entity for consulting fees. ChemX said it remained up to date with its financial reporting obligations after lodging its annual financial statements for the year ended 30 June 2026.
Annual Meetings Set for 5 November
Two annual general meetings are scheduled for 5 November 2026, covering the company’s 2025 and 2026 financial years. Those meetings are the next stated corporate milestone as ChemX continues to pursue a possible restructuring outcome, but the filing does not say that shareholder approval at either meeting would by itself restore trading.
The immediate tension is straightforward: the facility provides limited operating time, while the company’s route back to the market remains prospective. With the loan due to mature in March 2027 and the available funding declining as costs are incurred, the next material question is whether ChemX can complete a recapitalisation before its financing runway becomes the more urgent issue.
Bottom Line?
ChemX has funding to continue its restructuring work for now, but the path from an interest-bearing loan and suspended shares to a completed relisting remains unconfirmed.
Questions in the middle?
- Will ChemX secure and complete a recapitalisation before the Ovay facility matures in March 2027?
- What terms, including issue price and dilution, would apply if the loan converts into shares through a relisting capital raising?
- Will the 5 November annual general meetings produce any decisions that materially advance the company’s return to trading?